2022 Year in Review: Kerrie Julian, Margulies Perruzzi

What was your most important professional accomplishment or most notable project, deal, or transaction in 2022?
Joining Margulies Perruzzi, a firm I’ve admired for many years, as director of science strategy. In this role, I am responsible for lending my expertise to projects, managing and recruiting staff, and developing new client relationships. With an extensive science portfolio, Margulies Perruzzi specializes in life sciences, medical devices, R&D, and manufacturing projects. Margulies Perruzzi has worked with a wide range of industry leaders, including IQHQ, Strand Therapeutics, Azenta, Avencell, Boston Scientific, and many others. The culture is collaborative, engaging, and fun. I feel very supported by leadership and look forward to 2023.

What emerging trends will drive investment and development in 2023?
The Greater Boston life science and science/technology real estate markets plateaued this year from previous years; however, it’s still an exciting time. Several new lab buildings will be coming online in the next few years, and we are seeing an increased demand for manufacturing and cGMP facilities. Mergers and acquisitions will be prevalent in 2023 as some smaller companies may see the need to join forces with larger established companies.